Innogen Licenses Efsubaglutide in Selected Emerging Markets

Guangzhou Innogen disclosed November 19 a 15-year regional commercialization and development license with Arcera for its China-marketed GLP-1 medicine efsubaglutide alfa. The transaction tests whether a domestic metabolic asset can be registered and launched…





